Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
Katrina J. Church, the Senior Vice President and Chief Compliance Officer of Bioventus Inc. (NASDAQ:BVS), a $633 million market cap healthcare company, recently sold a portion of her holdings in the company. According to InvestingPro data, the stock currently trades slightly below its Fair Value despite showing strong momentum with a 78% return over the past year. According to a Form 4 filing with the Securities and Exchange Commission, Church sold 1,018 shares of Class A common stock on March 17, 2025. The shares were sold at a weighted average price of $9.75, resulting in a total transaction value of $9,925. The transaction comes as the stock has experienced a notable 9.3% decline over the past week, though analysts maintain price targets ranging from $13 to $17.
The sale was part of a pre-arranged trading plan under Rule 10b5-1, which allows company insiders to sell a predetermined number of shares at a predetermined time. This particular transaction was executed to cover taxes upon the vesting of restricted stock units.
Following the sale, Church retains ownership of 52,540 shares of Bioventus. The transaction was part of a larger trade involving multiple employees of the company, with share prices ranging from $9.56 to $10.00.
In other recent news, Bioventus Inc. reported strong fourth-quarter 2024 earnings, surpassing revenue expectations. The company achieved a revenue of $154 million, exceeding the forecasted $145.16 million and marking a 14% year-over-year increase. This performance was driven by strategic investments and successful product lines, particularly in the Surgical Solutions and Pain Treatments segments. Bioventus also reported a full-year adjusted EBITDA of $109 million, reflecting a 23% rise from the previous year. The company managed to pay down nearly $50 million in debt, further improving its financial health. Looking ahead, Bioventus projects 2025 net sales to range between $560 million and $570 million, indicating 6-8% organic growth. The company aims for an adjusted EBITDA of $112-$116 million, with plans to expand their Ultrasonics segment and enhance international market strategies. Analyst firm Craig Hallum noted the company’s above-market growth expectations, particularly in the Pain Treatments segment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.